Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

European Drug Development Project Targets Gram-negative Bacteria

By BiotechDaily International staff writers
Posted on 25 Feb 2014
Image: Microscopic image of gram-negative Pseudomonas aeruginosa bacteria (pink-red rods) (Photo courtesy of Wikimedia Commons).
Image: Microscopic image of gram-negative Pseudomonas aeruginosa bacteria (pink-red rods) (Photo courtesy of Wikimedia Commons).
A consortium of European universities, research institutes, and biopharmaceutical companies has been established to discover and develop novel new antibiotics, especially for treatment of gram-negative bacterial infections.

The ENABLE (European Gram-Negative Antibacterial Engine) project brings together more than 30 European universities and companies, in a six-year program funded by the Innovative Medicines Initiative (Brussels, Belgium), a joint undertaking between the European Union and the pharmaceutical industry association EFPIA (European Federation of Pharmaceutical Industries and Associations – Brussels, Belgium).

The ENABLE project, which is the third within the ND4BB (New Drugs for Bad Bugs) series, spans 13 countries and charges the 32 partners with the mission of establishing a significant antibacterial drug discovery platform for the progression of research programs through discovery and Phase 1 clinical trials.

The primary target of the ENABLE project is gram-negative bacteria. Medically relevant gram-negative bacilli include a multitude of species. Some of them cause primarily respiratory problems (Hemophilus influenzae, Klebsiella pneumoniae, Legionella pneumophila, Pseudomonas aeruginosa), primarily urinary problems (Escherichia coli, Proteus mirabilis, Enterobacter cloacae, Serratia marcescens), and primarily gastrointestinal problems (Helicobacter pylori, Salmonella enteritidis, Salmonella typhi).

One of the several unique characteristics of these bacteria is the structure of the outer membrane. The outer leaflet of the membrane comprises a complex lipopolysaccharide (LPS) whose lipid portion acts as an endotoxin. If LPS enters the circulatory system, it causes a toxic reaction, with the sufferer developing a high temperature, high respiration rate, and low blood pressure. This may lead to endotoxic shock, which can be fatal. This outer membrane protects the bacteria from several antibiotics, dyes, and detergents that would normally damage either the inner membrane or the cell wall's (peptidoglycan). The outer membrane provides these bacteria with resistance to antibacterial agents such as lysozyme and penicillin.

MEDINA (Granada, Spain), one of the participants in the ENABLE project, is an independent nonprofit research and development organization established jointly by the pharmaceutical company Merck Sharp and Dohme, the government of Andalucia, and the University of Granada. Its researchers are actively seeking new molecules from its proprietary natural product libraries to develop new medicines that respond to unmet medical needs.

“MEDINA brings to the project one of the novel antibiotic molecules that will be developed within this partnership. Our participation in this program represents a fantastic opportunity to jointly develop one of our most advanced compounds in our pipeline,” said Dr. Olga Genilloud, scientific director of MEDINA. “MEDINA offers a unique and longstanding expertise in drug discovery. We are committed with the global research effort for the discovery of new antibiotics, as continuity of a long history of success which has resulted in some of the most important breakthrough drugs available to patients today.”

Related Links:

Innovative Medicines Initiative
European Federation of Pharmaceutical Industries and Associations
MEDINA



Channels

Genomics/Proteomics

view channel
Image: In mice, mitochondria (green) in healthy (left) and Mfn1-deficient heart muscle cells (center) are organized in a linear arrangement, but the organelles are enlarged and disorganized in Mfn2-deficient cells (right) (Photo courtesy of the Rockefeller Press).

Cell Biologists Find That Certain Mitochondrial Diseases Stem from Coenzyme Q10 Depletion

A team of German cell biologists has linked the development of certain mitochondrial-linked diseases to depletion of the organelles' pool of coenzyme Q10 brought about by mutation in the MFN2 gene, which... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.